Immunotherapy combinations based on nivolumab entail lower costs for grade 3/4 adverse events than those using pembrolizumab, a finding that could inform treatment decisions.
Medscape Medical News
Nivolumab or Pembrolizumab Combos in Advanced Kidney Cancer?
